---
layout: minimal-medicine
title: Alemtuzumab
---

# Alemtuzumab
### Generic Name
Alemtuzumab

### Usage

Alemtuzumab is a medication used to treat two distinct conditions:

* **Relapsing forms of multiple sclerosis (MS):**  Alemtuzumab is employed to manage relapsing-remitting MS, a type of MS characterized by periods of relapse (worsening of symptoms) followed by remission (improvement or stabilization of symptoms).  It works by reducing the activity of the immune system, which plays a significant role in the damage to the myelin sheath (protective covering of nerve fibers) in MS.

* **B-cell chronic lymphocytic leukemia (B-CLL):**  Alemtuzumab is also indicated as a single-agent therapy for B-CLL, a type of cancer affecting the white blood cells.  It targets and destroys cancerous B-cells by binding to a specific protein on their surface (CD52).


### Dosage

Dosage varies considerably depending on the condition being treated and the route of administration (intravenous [IV] is the standard, but subcutaneous [SubQ] is off-label):

**B-cell Chronic Lymphocytic Leukemia (B-CLL) - IV Administration:**

Dosage begins with a low dose (3 mg/day) and gradually increases until a maximum of 30 mg/day is reached, given three times per week on alternate days for a total of 12 weeks.  This escalation strategy is crucial to minimize infusion reactions.  Premedication with diphenhydramine and acetaminophen is typically required before each infusion.  Prophylactic antibiotics (trimethoprim/sulfamethoxazole) and antiviral medication (famciclovir) are also administered to reduce the risk of infection.

**B-cell Chronic Lymphocytic Leukemia (B-CLL) - Subcutaneous (Off-Label) Administration:**

Several off-label subcutaneous dosing regimens exist, typically involving a dose escalation phase followed by a maintenance phase. It's vital to consult with a healthcare professional for specific instructions on subcutaneous administration as it is not formally approved by regulatory agencies for this indication.

**Relapsing-Remitting Multiple Sclerosis (MS) - IV Administration:**

The treatment involves two treatment courses, separated by 12 months. The first course consists of 12 mg/day for five consecutive days (total 60 mg), and the second course involves 12 mg/day for three consecutive days (total 36 mg). Subsequent courses may be considered at least 12 months after the last dose, if necessary. High-dose corticosteroids are administered before and after each Alemtuzumab infusion. Antiviral prophylaxis is also essential.

**Pediatric Dosage:**

The safety and efficacy of Alemtuzumab in children have not been established.


### Side Effects

Alemtuzumab can cause various side effects, ranging from common to rare and serious.  It is essential to consult a healthcare provider if any adverse effects occur.

**Common Side Effects (Vary by Indication and Individual):**

* Fatigue
* Headache
* Nausea
* Diarrhea
* Skin rash
* Infusion reactions (fever, chills, hypotension)
* Lymphocytopenia (low lymphocyte count)
* Infections (upper respiratory tract infections, etc.)
* Thyroid disorders


**Serious but Less Common Side Effects:**

* Autoimmune diseases (e.g., immune thrombocytopenia, hemolytic anemia, autoimmune hepatitis, etc.)
* Severe infections (including opportunistic infections)
* Pancytopenia (severe decrease in all blood cell types)
* Stroke
* Malignancies (cancers)
* Infusion reactions (anaphylaxis)
* Progressive multifocal leukoencephalopathy (PML) - a rare and serious brain infection.



### How it Works

Alemtuzumab is a monoclonal antibody that targets CD52, a protein found on the surface of various immune cells, including lymphocytes (B cells and T cells) and monocytes. By binding to CD52, Alemtuzumab leads to the destruction of these cells. In MS, this helps reduce the immune system's attack on the myelin sheath.  In B-CLL, it targets and destroys cancerous B-cells.  The depletion of immune cells is a significant mechanism of action and contributes to both the therapeutic effect and the increased risk of infections.

### Precautions

* **Hypersensitivity:** Alemtuzumab is contraindicated in patients with hypersensitivity to it or its components.
* **Infections:** Increased risk of serious infections; prophylactic measures are typically required.
* **Autoimmune Diseases:** Alemtuzumab can trigger or worsen autoimmune conditions.
* **Bone Marrow Suppression:**  Risk of bone marrow suppression, including cytopenias (low blood cell counts).
* **Pregnancy and Breastfeeding:**  Use in pregnancy and breastfeeding should be carefully considered due to potential risks to the fetus or infant.  Effective contraception is recommended.
* **Drug Interactions:** Alemtuzumab may interact with other medications, especially immunosuppressants.  Consult your healthcare provider about all medications you are taking.
* **Other Precautions:** Individuals with heart conditions, hypertension, or a history of stroke need to be monitored closely.  Regular blood tests and monitoring for infections are crucial.

### FAQs

* **How long does Alemtuzumab treatment last?** The duration varies greatly depending on the condition and the individual's response to treatment; your healthcare provider will determine the appropriate duration.

* **How is Alemtuzumab administered?**  It's typically administered intravenously (IV) via infusion over a specific period.

* **What should I do if I miss a dose?** Consult with your healthcare provider immediately.

* **How should I store Alemtuzumab?** Store as directed by your healthcare professional or the medication packaging.

* **What are the long-term effects of Alemtuzumab?**  Long-term effects can include an increased risk of certain infections and autoimmune disorders.  Regular follow-up care is crucial.

* **Is Alemtuzumab safe for everyone?**  No. It's contraindicated in certain individuals (e.g., those with hypersensitivity or active infections).  Your healthcare provider will assess your suitability for this medication.


**Disclaimer:** *This information is intended for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before starting or changing any medication.*
